Intelligent Bio Solutions Inc. announced its expansion into the New Zealand market, representing a significant milestone in the Company's growth strategy for its Intelligent Fingerprinting Drug Screening System. Drug-related harm in New Zealand equates to a staggering $1.9 billion each year, with significant societal consequences across communities, workplaces and more. New Zealand employers have a responsibility under the Health and Safety in Employment Act 1992 (HSE Act) to ensure the provision of a safe workplace and take all reasonable measures to safeguard employees while at work.

The HSE Act further requires significant hazards to employees, such as the behaviour of an employee affected by alcohol or drugs, to be eliminated, isolated and minimized. The company's primary focus is to meet the screening needs and support the health and safety initiatives of businesses across New Zealand and around the world. Drawing on success in Australia over the past six months, the company aim to continue this progress in New Zealand and other markets by offering an alternative and innovative solution that places a strong emphasis on operational efficiency, fitness for duty, and employee privacy and dignity.

The company's Intelligent Finger printing Drug Screening System is currently available throughout Australia, the United Kingdom, South America, and parts of Europe and Asia, including Spain and Nepal. In addition to these locations, the Company's growth plan includes further expansion throughout Asia Pacific, the United States and Canada.